InspireMD Q4 net loss widens to $9.2M; revenue up 11%; FDA approval for CGuard Prime expected H1 2025

InspireMD, Inc.

Q4 revenue rose 10.7% YoY to $1.95M; gross profit fell 7.1% to $469K as COGS grew faster.
Net loss widened to $9.17M ($0.19/sh) from $5.41M ($0.16/sh); operating expenses surged 56% to $9.84M.
Full-year 2024 revenue $7.01M (+13% YoY); net loss $32.0M ($0.76/sh) vs $19.9M ($0.82/sh).
Cash and marketable securities $34.6M at Dec 31, 2024, down from $39.0M a year earlier.
Submitted PMA to FDA for CGuard Prime; enrolled first patients in CGUARDIANS II TCAR study; expects US approval H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.